With over 25 years of average experience in the field of Biotech/pharmaceutical development/Government regulatory expertise.
By combining robust expertise, proprietary patented algorithms and existing regulatory knowledge of pharmacogenomics and pharmacovigilance and medical affairs we are able to design offerings to both the biotech/pharma sector and directly to patients to allow them to manage their choice of medications and increased their awareness when managing their disease with their health care partnerships.
Due to the increased of regulatory scrutiny and digital health initiatives worldwide Medgenie is at the forefront of innovation in the field.
The Story
Medgenie is an emergent innovative company with a national and international base in Switzerland and the United States.
Risks and Challenges
Development complexity
Creating a robust, scalable, and user-friendly platform tailored to both biotech/pharma and patients is a significant technical undertaking. Ensuring it meets the unique needs of diverse users—Patients and industries—will require time, expertise, and rigorous testing
High Upfront Costs
Building a full-featured software platform with AI integration demands substantial initial investment. Costs for experienced developers, infrastructure, compliance, and marketing must be carefully managed to stay on track.
Market Entrenchment
We’re entering a space dominated by established players with a different clientele. The current solutions are targeted to the pharmacies and pharmacists in hospital settings with a lack of solutions to the industry or the patient. Gaining traction will require not only a superior product but also a strong go-to-market strategy and industry and regulatory support.
Regulatory and Data Security Compliance
Handling sensitive project and client data means complying with data protection regulations and cybersecurity standards, which requires ongoing attention and investment.
Regulatory FDA/EMA/Swiss Medic, etc compliance with regulatory bodies requires expertise.
Regulatory FDA/EMA/Swiss Medic, etc compliance with regulatory bodies requires expertise.
Adoption Curve
Even with a better product, changing how companies operate takes time. Industry users may be resistant to add to their already familiar flows, so clear value and ease of use must be demonstrated from day one. Patient adoption will require marketing to the grassroot platforms and patient support organizations.
Rewards
Medgenie intends to have a series A or angel investors for initial investment
The series A investment has a target of a minimum of 3 million USD convertable to preferred Stock for 10 % company share.
Exit Strategy
Exit strategy at 3 years or sooner at a target initial Market Cap of 10 million.
Flexible Convertible shares and Pre-IPO strategy.
Flexible Convertible shares and Pre-IPO strategy.